The ASCO Annual Meeting is hosted by the American Society of Clinical Oncology. The meeting offers presentations on the latest research in oncology care.
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
ASCO 2025: How AI-Powered Tools Are Reshaping Oncology Data Capture and Clinical Decision-Making
June 30th 2025Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.
Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC
June 11th 2025Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).
ASCO 2025: Asciminib Demonstrates Superiority Compared With Nilotinib in Ph+ CML-CP
June 11th 2025Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.
Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression
June 6th 2025Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.